Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry
| Autor: | Emilia Paron, Melonie Burrows, Jessica Blavignac, Ronald Goldenberg, Nadege Fils-Aimé, Alan Bell, Will Cheng, Maxime Barakat |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Canada medicine.medical_specialty Hypercholesterolemia Population Colesevelam Hydrochloride Type 2 diabetes 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine Azilsartan medicine Humans Hypoglycemic Agents 030212 general & internal medicine education Routine care Antihypertensive Agents Aged Oxadiazoles education.field_of_study Colesevelam business.industry Anticholesteremic Agents Chlorthalidone Middle Aged medicine.disease Metformin Diabetes Mellitus Type 2 Hypertension Cohort Cardiology Benzimidazoles Drug Therapy Combination Female Observational study Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of Cardiology. 76:385-394 |
| ISSN: | 0914-5087 |
| Popis: | Background Regional differences in the profile and treatment strategies of patients with cardiometabolic diseases have been studied in several different countries. The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry was designed to evaluate patient profiles and medical management of cardiometabolic diseases in routine clinical care settings across Canada. Primary objectives were to (1) evaluate regional variability of patient profiles with cardiometabolic disease(s) and (2) assess treatment differences of patients treated for type 2 diabetes (T2D), hypercholesterolemia (HCh), and hypertension (HTN) across Canada. Methods CV-CARE is a multi-center, observational, prospective registry that enrolled Canadian patients treated with metformin-extended release (MetER) for T2D, colesevelam (C) for HCh, azilsartan (AZI) for mild-to-moderate essential HTN and azilsartan/chlorthalidone (AZI/CHL) for severe, essential HTN. Patient characteristics and treatments were assessed at baseline. Results The registry enrolled 6960 patients, with a total of 4194 patients making up the primary analysis population [MetER (n = 995); C (n = 1639); AZI (n = 1364); AZI/CHL (n = 498)]. First-line use of MetER was more common in British Columbia (BC; 45.5%) compared to Ontario (ON; 29.8%), and Quebec (QC; 12.9%). C treatment for HCh was used as monotherapy most readily in BC (68.7%) compared with QC (59.7%) and ON (35.8%). Dual action of low-density lipoprotein cholesterol and hemoglobin A1c reduction was the predominant reason for C add-on therapy (46.8%), with highest usage seen in ON (62.9%). AZI treatment for HTN was most frequently used in BC (43.8%), and AZI/CHL was most commonly used in ON (12.0%). First-line use of AZI was more common in QC (50%) vs. ON (34.9%) and BC (24.1%). The primary reason for switching to AZI and AZI/CHL from prior treatment was lack of efficacy across provinces. Conclusion This is the first regional description of the CV-CARE cohort. Significant variations in both baseline profile and treatments were observed which could have an impact on long-term outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect